Fisher Asset Management LLC reduced its stake in Stryker Corporation (NYSE: SYK) by 5.8% during the fourth quarter, selling 192,839 shares and retaining a position valued at approximately $1.10 billion. This move coincides with Stryker's recent quarterly earnings miss, where the company reported EPS of $2.60 against expectations of $2.98 and revenue of $6.02 billion versus an estimated $6.34 billion, despite a 2.6% year-over-year revenue increase.
Analyst sentiment has shifted toward caution following the earnings miss, with several major firms lowering price targets or downgrading ratings. UBS cut its target to $380 with a neutral rating, while TD Cowen and Goldman Sachs also issued neutral or hold ratings. Despite these headwinds, the stock maintains a 'Moderate Buy' consensus with an average price target of $395.48, though recent downgrades suggest growing skepticism among Wall Street analysts.
Institutional ownership remains robust, with Vanguard increasing its stake by 0.4% and AllianceBernstein raising theirs by 13.3%. However, insider activity presents a mixed signal; while major funds are accumulating, Stryker VP M Kathryn Fink sold 95.19% of her holdings for nearly $1 million in May. The company also declared a quarterly dividend of $0.88 per share, payable on July 31st to shareholders of record on June 30th.
📉 Fisher Asset Management trimmed Stryker position by 5.8% in Q4.
💰 Stryker missed Q4 EPS and revenue estimates despite growth.
📊 Major banks issued neutral or hold ratings after earnings miss.
🏦 Vanguard and AllianceBernstein increased stakes showing long-term confidence.
💸 VP Kathryn Fink sold nearly all shares signaling insider caution.
📉 Fisher Asset Management trimmed its Stryker position by 5.8% in Q4, selling 192,839 shares while retaining a $1.10 billion stake.
💰 Stryker reported Q4 EPS of $2.60 and revenue of $6.02 billion, missing analyst estimates for both metrics despite positive YoY revenue growth.
📊 Analyst consensus has weakened with UBS, TD Cowen, and Goldman Sachs issuing neutral or hold ratings following the earnings miss.
🏦 Major institutional investors like Vanguard and AllianceBernstein increased their stakes, indicating continued long-term confidence.
💸 VP M Kathryn Fink sold 95.19% of her shares for $992,075 in a May transaction, signaling insider caution.
📈 The stock trades at a PE ratio of 36.62 with a market cap of $121.29 billion and a current price near $316.
💵 Stryker declared a quarterly dividend of $0.88 per share, offering a yield of 1.1% to eligible investors.
🔮 The company provided FY 2026 EPS guidance ranging between $14.90 and $15.10.
Bullish Signals
Vanguard increased stake to 33.9 million shares.
Alliancebernstein raised position by 13.3% adding 741k shares.
Revenue grew 2.6% year-over-year to $6.02 billion.
Current ratio of 2.11 and debt-to-equity of 0.62.
Quarterly dividend of $0.88 per share with 1.1% yield.
Risk Factors
Missed EPS ($2.60 vs $2.98) and revenue ($6.02B vs $6.34B).
Analysts downgraded stock; UBS target cut to $380.
VP sold 95.19% holdings for nearly $1 million.
Trading below 50-day ($325.22) and 200-day ($349.76) averages.
Bullish Signals
Vanguard Group Inc. increased its stake in Stryker by 0.4% to own over 33.9 million shares, demonstrating strong institutional confidence.
Alliancebernstein L.P. significantly raised its position by 13.3% in the third quarter, adding over 741,000 shares to its portfolio.
Stryker achieved a 2.6% year-over-year revenue increase to $6.02 billion, showing underlying business growth despite missing earnings estimates.
The company maintains healthy financial metrics with a current ratio of 2.11 and a debt-to-equity ratio of only 0.62.
Stryker declared a quarterly dividend of $0.88 per share, providing a 1.1% yield to shareholders of record on June 30th.
Risk Factors
Stryker missed analyst expectations for both EPS ($2.60 vs $2.98) and revenue ($6.02B vs $6.34B) in the most recent quarter.
Several major analysts have downgraded the stock or lowered price targets, including UBS cutting its target to $380 with a neutral rating.
VP M Kathryn Fink sold 95.19% of her personal holdings for nearly $1 million, indicating significant insider selling activity.
The stock is trading below its 50-day ($325.22) and 200-day ($349.76) moving averages, suggesting short-term weakness.
Stryker Corporation (NYSE: SYK) announced the European launch of its Pangea Plating System, a new non-active implant platform designed for fracture fixation across the upper and lower extremities. The system combines thoughtfully designed plates with a streamlined instrumentation set to offer surgeons practical options for treating various fracture patterns while maintaining simplicity in the operating room.
The product was developed in collaboration with 26 orthopaedic surgeons globally, incorporating anatomical data to ensure proper plate fit across diverse patient populations. A key feature of the Pangea system is its variable-angle plating design, which allows for flexible screw placement angles to improve surgical fit and healing outcomes without adding unnecessary complexity.
Prof. Alex Trompeter of St. George's University Hospital in London completed the first clinical case in Europe with the new system. Industry experts, including Dr. Arvind von Keudell from Harvard Medical School, praised the device for supporting consistent workflows and helping surgeons adapt to different fracture patterns effectively.
🚀 Stryker launches Pangea Plating System in Europe for fractures.
👥 Platform developed with 26 global orthopaedic surgeons.
🔧 Features variable-angle plating for flexible screw placement.
🏥 Prof. Alex Trompeter performs first European clinical case.
🚀 Stryker launches the Pangea Plating System in Europe for treating a wide range of fracture patterns.
👥 The platform was developed through collaboration with 26 orthopaedic surgeons from around the world.
🔧 The system features variable-angle plating to allow flexible screw placement for improved surgical fit.
🏥 Prof. Alex Trompeter completed the first clinical case in Europe at St. George's University Hospital.
💡 The non-active implants are designed to provide temporary stabilization with simplified operating room workflows.
🌍 The launch expands access to Stryker's trauma portfolio and reflects a focus on evolving trauma care needs.
Bullish Signals
Variable-angle plating improves fit and reduces complications.
Data from 26 surgeons supports diverse patient fits.
Expands Stryker's European trauma market access.
Bullish Signals
The Pangea Plating System is designed to simplify fracture surgery by combining thoughtfully designed plates with a streamlined instrumentation set.
Variable-angle plating technology offers flexibility in screw placement, which can improve surgical fit and potentially reduce complication rates.
The system incorporates global anatomical data collected from 26 surgeons to support plate fit across diverse patient populations.
Industry leaders highlight the device's ability to support consistent workflows while offering adaptability for different fracture patterns.
The European launch expands market access for Stryker's trauma portfolio and reinforces its commitment to developing solutions that enhance surgical efficiency.
Truist lowered its price target for Stryker Corporation (NYSE:SYK) from $380 to $330 while maintaining a Hold rating following updates to its financial model after the medical technology company's first-quarter results. The reduction reflects disruptions caused by a cyber-related incident that affected earnings timing and flow, alongside broader valuation pressure in the large-cap medical technology sector which has reduced multiples across peers. Despite this analyst downgrade, Stryker reaffirmed on April 30 its fiscal 2026 outlook with adjusted earnings per share guidance between $14.90 and $15.10, slightly above consensus expectations. The company also projected organic net sales growth of 8.0% to 9.5%, supported by modestly positive pricing trends and a slight foreign exchange tailwind assuming current currency levels persist.
Stryker is based in Portage, Michigan, and develops products in orthopaedics, surgical equipment, and neurotechnology for patients worldwide. While the article notes certain AI stocks may offer greater upside potential or benefit from tariffs during the Trump era, these recommendations are tangential to the core analysis of Stryker's current market position and financial guidance. The cyber incident remains a key factor influencing the short-term outlook, as investors await clarity on operational recovery and earnings normalization alongside industry-wide valuation adjustments.
📉 Truist cut Stryker price target to $330 due to valuation pressure and a Q1 cyber incident.
🏭 Company reaffirmed FY26 EPS guidance of $14.90-$15.10 with expected 8-9.5% organic sales growth.
⚖️ Analysts maintain Hold ratings, though some favor AI stocks over Stryker for better upside.
📉 Truist lowered its Stryker (SYK) price target from $380 to $330, citing valuation pressure.
⚖️ Analysts maintain a Hold rating on the stock despite the price target reduction.
💻 A cyber-related incident in Q1 affected earnings timing and flow, influencing the outlook adjustment.
📊 The firm updated its financial model based on first quarter results before making the revision.
🌍 Broader valuation pressure across large-cap medical technology peers contributed to the lower outlook.
🏭 Stryker reaffirmed fiscal 2026 earnings per share guidance of $14.90 to $15.10, above consensus.
💹 The company expects organic net sales growth between 8.0% and 9.5%, supported by pricing trends.
💵 Foreign exchange is projected to provide a slight tailwind to revenue and adjusted earnings per share.
🏥 Stryker is a global medical technology company based in Portage specializing in orthopaedics, surgical equipment, and neurotechnology.
🤖 Analysts suggest AI stocks may offer greater upside potential compared to SYK currently.
📜 The article notes no specific disclosure was provided regarding the authors' positions or transactions.
Risk Factors
Truist lowered SYK price target $380 to $330 due to valuation pressure.
Cyber incident in Q1 disrupted earnings timing and negatively impacted flows.
Valuation pressure across medical peers reduces multiples and outlook for SYK.
Bullish Signals
Stryker Corporation reaffirmed its fiscal 2026 outlook, maintaining adjusted earnings per share guidance between $14.90 and $15.10, which is slightly above consensus expectations.
The company projected organic net sales growth between 8.0% and 9.5%, supported by modestly positive pricing trends that indicate strong demand for its medical technology products.
Management expects foreign exchange to provide a slight tailwind to both revenue and adjusted earnings per share, assuming current currency levels persist, which suggests stable operational expectations for the year ahead.
Risk Factors
Truist Securities lowered its price target for Stryker Corporation (SYK) from $380 to $330, signaling valuation pressure on the stock.
The lower price target also reflected negative impacts from a cyber-related incident in the first quarter that disrupted earnings timing and flow.
Broader valuation pressure across large-cap medical technology peers is contributing to reduced multiples and a downgraded outlook for SYK.
Stryker Corporation (NYSE:SYK) reported disappointing first-quarter financial results, with statutory earnings per share missing analyst forecasts by 15% at US$1.93 per share. Revenue came in marginally below expectations at US$6.0 billion, signaling a tougher period for the medical technology firm as the market reassesses its outlook following this underperformance.
Despite the near-term miss, 26 analysts maintain a consensus forecast projecting Stryker revenues to reach US$27.3 billion in 2026, representing a satisfactory 7.9% growth compared to the previous 12 months. Analyst expectations for future earnings have been revised upward significantly, with estimated statutory EPS predicted to soar 46% to US$12.74, up from the pre-report estimate of US$12.16 per share, indicating growing long-term optimism despite current earnings weakness.
The average analyst price target decreased by 7.1% to US$389 following the report, suggesting concerns about the stock's intrinsic value that outweighed the improved earnings outlook. However, the growth trajectory remains robust; revenue is forecast to grow at an annualised rate of 11% through 2026, which aligns with the company's historical 9.9% five-year growth and substantially outpaces the industry average forecast of 8.0% per year for similar companies.
🔮 Statutory EPS forecast jumps 46% to US$12.74 for 2026.
⚠️ Average price target dropped 7.1% amid divergent analyst views.
📈 Long-term growth rate of 11% outpaces the industry average.
📉 Stryker Corporation (NYSE:SYK) reported first-quarter earnings with EPS of US$1.93, missing analyst forecasts by 15%.
💰 Revenue came in marginally short of estimates at US$6.0 billion despite the significant miss in profitability.
🔮 Analysts now forecast a 46% surge in statutory EPS to US$12.74 for 2026, up from previous estimates of US$12.16.
📈 Consensus revenue expectations for 2026 stand at US$27.3 billion, reflecting a 7.9% improvement over the last 12 months.
🧊 The annualized revenue growth rate is forecast to reach 11% through 2026, outpacing the industry average of 8.0%.
📉 The average price target for Stryker fell by 7.1% to US$389 following the disappointing quarterly results.
📊 Analysts show a divergence in views with optimistic targets reaching US$465 and pessimistic ones as low as US$315.
🤖 Long-term earnings power is considered more critical than next year's profits for investors evaluating the stock.
⚠️ A single warning sign has been identified by analysts that warrants attention before forming investment conclusions.
🧾 This analysis is based on historical data and forecasts from Simply Wall St without constituting financial advice.
Bullish Signals
Analysts upgraded EPS estimates following Stryker's latest results.
Consensus EPS forecast projects 46% year-over-year growth to US$12.74 by 2026.
Revenue forecasts show 11% annualized growth, beating the 8.0% industry average.
Long-term revenue outlook indicates a 7.9% improvement with US$27.3b consensus for 2026.
Analysts reconfirmed revenue numbers as company tracks well against expectations.
Risk Factors
Missed EPS forecast by 15%, signaling immediate performance weakness.
Average price target fell 7.1% to US$389 amid pessimism.
Widened analyst price targets (US$315-US$465) show high uncertainty.
One explicit warning sign suggests hidden risks for investors.
Bullish Signals
Analysts have upgraded their earnings per share (EPS) estimates, reflecting a clear increase in optimism toward Stryker Corporation following the latest results.
The consensus forecast projects statutory EPS to soar 46% year-over-year, reaching US$12.74 per share by 2026.
Revenue forecasts indicate an annualized growth rate of 11%, which is substantially higher than the industry average forecast of 8.0% over the same period.
Long-term revenue outlook shows a satisfactory 7.9% improvement compared to the last 12 months, with consensus forecasts for US$27.3b in 2026.
Analysts have reconfirmed their revenue numbers, suggesting the company is tracking well against high-level expectations.
Risk Factors
Stryker Corporation missed its earnings per share (EPS) forecast by 15%, recording just US$1.93 per share, which signals immediate performance weakness.
Despite the optimistic long-term analyst revenue and EPS forecasts, the average price target has fallen 7.1% to US$389, indicating growing pessimism about the stock's current intrinsic value.
Analysts have widened their price target range significantly, with targets ranging from a high of US$465 to a low of US$315, reflecting substantial disagreement and uncertainty about the stock's fair value.
The article explicitly flags one warning sign for Stryker, suggesting there are hidden risks or fundamental issues that investors should be aware of before being too enthusiastic about the earnings beat on forecasts.
Stryker Corporation has officially completed the acquisition of Amplitude Vascular Systems, a deal aimed at expanding its presence in the intravascular lithotripsy (IVL) market. This platform, known as the Pulse, utilizes pressure waves generated by carbon dioxide delivered through a balloon catheter to fracture calcified plaque in narrowed arteries, thereby restoring blood flow in both coronary and peripheral vessels. The transaction was finalized less than a month after it was announced, though specific financial terms were not disclosed.
This acquisition allows Stryker to bolster its peripheral vascular portfolio, which already includes the clot-removal business acquired from Inari Medical for approximately $4.9 billion last year. The move aligns Stryker with other major industry players, including Johnson & Johnson, Boston Scientific, and Abbott, who have recently made significant investments or acquisitions in the IVL space to address severely calcified arterial disease. Notably, J&J's acquisition of Shockwave Medical for $13.1 billion last year stands as the industry's largest deal of 2024.
Stryker CEO Kevin Lobo confirmed the company's continued focus on mergers and acquisitions, stating that they possess sufficient cash reserves to pursue further deals through the end of the current year and into 2027. He highlighted an active pipeline and expressed investor confidence in their M&A strategy for the upcoming period. Meanwhile, Amplitude Vascular began enrolling patients in a pivotal U.S. study in 2024 and raised $36 million in January 2025 to support device launch and clinical trials for treating coronary and carotid disease. The integration of this technology is expected to strengthen Stryker's competitive position against rivals actively seeking approvals and market entry in the growing IVL sector.
🏷️ Stryker officially closed Amplitude's acquisition under undisclosed financial terms.
🔬 The deal adds Pulse IVL technology for treating severely calcified arteries.
🚀 Stryker plans continued M&A activity through 2027 to strengthen its vascular portfolio.
⚖️ Competitors like J&J and Boston Scientific also entered the IVL market recently.
📰 Stryker has officially completed its acquisition of Amplitude Vascular Systems, finalizing the deal less than a month after it was initially announced.
💸 The financial terms of the acquisition were not disclosed in the report.
🩺 Amplitude's primary technology is the Pulse intravascular lithotripsy (IVL) platform, designed to treat severely calcified arterial disease using pressure waves.
🔬 The IVL device utilizes carbon dioxide to generate pressure waves delivered through a balloon catheter to fracture calcium and expand narrowed vessels.
🚀 This acquisition allows Stryker to enter the booming intravascular lithotripsy market, which has attracted major investment from competitors like Johnson & Johnson, Boston Scientific, and Abbott.
🔄 Stryker stated that adding this IVL platform will strengthen its peripheral vascular portfolio, building on the Inari Medical clot-removal business acquired for $4.9 billion last year.
🧠 CEO Kevin Lobo confirmed on an earnings call that Stryker expects to remain active in mergers and acquisitions through the end of 2025 and into 2027.
💰 The company emphasized it has sufficient cash reserves in its pipeline to execute additional deals, signaling continued aggressive growth strategy.
⚖️ Johnson & Johnson previously made the industry's biggest acquisition in 2024 by purchasing Shockwave Medical for $13.1 billion to enter the IVL space.
📈 Boston Scientific also moved into the market last year with the acquisition of Bolt Medical, paying up to $664 million for its remaining stake.
🏥 Abbott approved its IVL clinical trial in the U.S. in 2025 following its 2023 acquisition of Cardiovascular Systems for $890 million.
🧪 Amplitude began enrolling patients in a pivotal U.S. IVL study in 2024, focusing on treating coronary and carotid disease.
💹 In January 2025, Amplitude raised $36 million to support device launch and further U.S. trials for calcified artery treatments.
🔍 The technology specifically targets peripheral artery disease and coronary artery disease where vessel narrowing reduces blood flow to limbs.
📅 All reported financial transactions and regulatory approvals mentioned are tied to fiscal years or specific dates up through early 2025.
Bullish Signals
Stryker closed Amplitude Vascular deal under one month.
Access to booming IVL market rivals J&J, Boston Scientific.
Strong financial confidence with active M&A pipeline to 2027.
Pulse platform targets severe calcified arterial disease.
Amplitude raised $36M for launches and clinical trials.
Aggressive competitor acquisitions like J&J's $13.1B Shockwave deal intensify competition.
Undisclosed Amplitude acquisition terms leave investors uncertain about costs and earnings.
Stryker's plan for M&A through 2027 risks over-extending resources.
Market consolidation may squeeze margins for smaller entrants like Amplitude.
Amplitude raised $36M in Jan 2025, signaling high capital needs.
Bullish Signals
Stryker has successfully completed the acquisition of Amplitude Vascular Systems, rapidly closing the deal less than a month after the announcement.
The acquisition gives Stryker access to the booming intravascular lithotripsy (IVL) market, which has already attracted major investments from industry leaders like Johnson & Johnson, Boston Scientific, and Abbott.
Stryker signaled strong financial confidence by maintaining an active M&A pipeline through 2027, with CEO Kevin Lobo confirming the company has sufficient cash to execute further deals.
The Pulse platform acquired is designed for severe calcified arterial disease, a critical unmet need where competitors like Johnson & Johnson paid $13.1 billion for Shockwave Medical in 2024.
Amplitude raised $36 million in January 2025 to support device launches and U.S. clinical trials, demonstrating strong investor confidence in the technology's potential to treat coronary and carotid disease.
Stryker expands its peripheral vascular portfolio with a leading-edge lithotripsy solution, complementing its recent $4.9 billion acquisition of Inari Medical for clot removal.
Risk Factors
Competitors like Johnson & Johnson, Boston Scientific, and Abbott are aggressively pursuing the intravascular lithotripsy (IVL) market with multi-billion dollar acquisitions (e.g., J&J's $13.1 billion purchase of Shockwave Medical, Abbott's $890 million acquisition of Cardiovascular Systems), intensifying competition.
The financial terms for Stryker's Amplitude Vascular acquisition were not disclosed, leaving investors uncertain about the deal's cost and potential impact on future earnings.
Stryker plans to remain active in M&A activity through 2027, which may signal an over-extension of resources or a reliance on acquisitions rather than organic growth to drive value.
The competitive landscape suggests that other major players are consolidating rapidly, potentially squeezing margins for smaller entrants like the acquired Amplitude Vascular Systems in the long term.
Amplitude Vascular Systems recently raised $36 million in January 2025 to support U.S. trials, indicating the high capital requirements and risk profile associated with bringing new IVL technologies to market.
Stryker has officially completed its acquisition of Amplitude Vascular Systems, a privately held medical technology firm based in Boston that specializes in treating severely calcified arterial disease. This deal marks a significant strategic milestone for Stryker as it seeks to expand its peripheral vascular portfolio with next-generation intravascular lithotripsy (IVL) technology. The acquired company's core innovation utilizes carbon dioxide-generated pressure waves to effectively treat complex peripheral arterial disease, allowing physicians to manage challenging calcified lesions more efficiently.
Kevin Lobo, Chair and CEO of Stryker, emphasized that integrating Amplitude Vascular Systems' CO₂-based technology with Stryker's extensive resources will enhance the company's ability to support physicians and improve patient outcomes across the global medical device market. The target company was founded in 2017 by Hitinder Gurm, M.D., and Robert Chisena, Ph.D., and has been backed by notable global investors such as BioStar Capital and Cue Growth Partners.
The announcement is accompanied by a standard corporate introduction highlighting Stryker's leadership in MedSurg, Neurotechnology, and Orthopaedics, noting its impact on over 150 million patients annually. Contact information for investor relations and communications officers Nick Mead and Kim Montagnino was provided at the Portage, Michigan headquarters. While the press release includes a standard footer indicating it was published by a news wire service rather than directly by Markets Insider or Business Insider, the core content regarding the acquisition is substantial and specific to the company's strategic growth plans.
✅ Stryker acquired Amplitude Vascular Systems to add IVL lithotripsy technology.
👨⚕️ AVS founders and investors include Dr. Hitinder Gurm and BioStar Capital.
📉 Analysts Truist and Barclays reduced price targets amid the deal news.
🏛️ Stryker (NYSE: SYK) has officially completed its acquisition of privately held Amplitude Vascular Systems (AVS).
🌐 The deal brings next-generation intravascular lithotripsy (IVL) technology to Stryker's peripheral vascular portfolio.
💡 AVS utilizes innovative CO₂-generated pressure wave technology designed to treat complex peripheral arterial disease.
📍 AVS is a Boston-based medical device company founded in 2017 by Hitinder Gurm, M.D., and Robert Chisena, Ph.D.
💼 Key investors backing AVS include BioStar Capital and Cue Growth Partners.
🗣️ Stryker CEO Kevin Lobo stated the acquisition is a significant milestone for expanding their peripheral vascular capabilities.
🎯 The integration aims to combine AVS's technology with Stryker's global scale and resources to improve patient outcomes.
⚕️ Stryker impacts more than 150 million patients annually across MedSurg, Neurotechnology, and Orthopaedics.
💰 On May 7, 2026, Stryker also declared a quarterly dividend of $0.88 per share.
📉 Analyst Truist lowered its price target for Stryker to $330 from $380 prior to the acquisition news.
📉 Barclays simultaneously lowered its price target for Stryker to $394 from $469 around the same period.
🔄 The company faces conflicting analyst sentiments regarding its healthcare performance in early May 2026.
Bullish Signals
Stryker acquires Amplitude Vascular Systems for next-gen IVL tech.
Deal adds CO₂ pressure wave technology to Stryker portfolio.
Milestone expands peripheral vascular offerings and addresses arterial disease.
Company serves 150M+ patients annually across multiple medical segments.
Stryker declares $0.88 quarterly dividend effective May 7, 2026.
Risk Factors
Truist cut valuation target from $380 to $330 post-acquisition.
Barlarys downgraded price target from $469 to $394.
Analysts show mixed confidence despite acquisition milestone success.
Bullish Signals
Stryker has successfully completed the acquisition of Amplitude Vascular Systems to add next-generation intravascular lithotripsy (IVL) technology to its peripheral vascular portfolio.
The deal integrates AVS's innovative CO₂-generated pressure wave technology with Stryker's scale and resources to deliver solutions that support physicians and patient outcomes.
This acquisition is described as a significant milestone in expanding Stryker's peripheral vascular portfolio and enhancing its ability to address challenging arterial disease.
Stryker remains a global leader impacting more than 150 million patients annually across MedSurg, Neurotechnology, and Orthopaedics segments.
The company declared a quarterly dividend of $0.88 per share on May 7, 2026, returning value to shareholders.
Risk Factors
Stryker faces a lowered price target from Truist, which reduced its valuation guidance from $380 to $330 just days after completing the acquisition.
Barlarys also downgraded Stryker's stock price target significantly from $469 to $394, indicating analyst concern over recent developments or valuations.
Despite the acquisition being described as a 'significant milestone,' conflicting sentiments from investors and analysts suggest mixed confidence in Stryker's immediate future performance.
Stifel Nicolaus analyst Rick Wise initiated coverage for Stryker with a Buy rating and set a price target of $360, noting the company's current share price closed at $294.73. The analysis highlights that Stryker currently holds a Strong Buy consensus among analysts with an average price target of $401.19, representing approximately 28% upside from recent trading levels. Additionally, TipRanks identified DeepSeek as upgrading the stock to Buy with a lower price target of $326.
Conversely, Establishment Labs Holdings received a reiterated Buy rating from TD Cowen analyst Josh Jennings who set a price target at $95 against a share price closing near $70.23. The consensus for Establishment Labs is a Strong Buy with an average price target of $87.71, indicating roughly 29.5% upside. This positive sentiment was supported by Canaccord Genuity, which maintained a Buy rating on April 24 with a $90 target.
Beyond these specific upgrades, the broader analyst landscape for Stryker presents a mixed picture of recent adjustments. Goldman Sachs raised its price target to $361, suggesting confidence in near-term valuation. However, several other major firms have recently lowered their targets: Baird cut its target from $437 to $385, Bernstein reduced it from $465 to $410, Evercore ISI lowered it from $445 to $400, and JPMorgan decreased its target from $445 to $400.
📈 Stryker holds a consensus target of $401.19, offering 28% upside despite mixed analyst sentiment.
🏥 Establishment Labs maintains a Buy rating with an $87.71 target and 29.5% upside potential.
🔬 Individual analysts like Rick Wise and TD Cowen's Josh Jennings reaffirm positive ratings for both healthcare stocks.
⚠️ Investors should note third-party disclaimers regarding the source material and potential publisher compensation.
💡 Unlock hedge fund data on TipRanks for deeper insights into these healthcare opportunities.
📈 Analyst Rick Wise at Stifel Nicolaus maintained a Buy rating on Stryker (SYK) with a price target of $360.00, despite his personal track record showing a -2.2% average return and 43.8% success rate.
🏥 The healthcare sector is viewed as optimistic, supported by consensus ratings that show Strong Buy status for both Stryker and Establishment Labs Holdings (ESTA).
📊 Stryker currently has an analyst consensus price target of $401.19, representing a 28.0% upside from its closing price of $294.73.
🤖 TipRanks – DeepSeek upgraded Stryker to a Buy rating with a price target of $326.00 in a recent report.
🔬 Establishment Labs Holdings (ESTA) received a reiterated Buy rating from TD Cowen analyst Josh Jennings, who set a price target of $95.00 on shares closing at $70.23.
⭐ Analyst Josh Jennings at TD Cowen holds a 2-star rating with a 42.9% success rate and covers the Healthcare sector including Baxter International and Edwards Lifesciences.
📉 Recent analyst actions show mixed sentiment for Stryker, with Goldman Sachs raising its target to $361 while others like Baird, Bernstein, Evercore ISI, and JPMorgan lowered theirs.
🔍 Establishment Labs Holdings maintains a consensus price target of $87.71, which offers a 29.5% upside from current market levels.
🛡 Canaccord Genuity maintained a Buy rating on Establishment Labs Holdings with a $90.00 price target in a report issued on April 24.
⚠️ The article includes a disclaimer noting that the content is third-party material that the Globe and Mail has not reviewed or endorsed.
💰 Readers are encouraged to unlock hedge fund-level data via TipRanks for smarter investing decisions regarding these healthcare stocks.
📜 This content is syndicated, and the publisher may receive compensation for the placement of this article on their site.
Bullish Signals
Stryker (SYK) has Strong Buy consensus with $401.19 target.
Stifel maintains Stryker Buy at $360 vs current $294.73.
TipRanks upgraded Stryker to Buy with $326 target.
Establishment Labs (ESTA) has Strong Buy consensus at $87.71.
ETA offers 29.5% upside from current levels to $90 targets.
Risk Factors
Major banks cut SYK price targets despite bullish consensus.
Stifel analyst Rick Wise shows -2.2% avg returns and low reliability.
Institutional caution persists despite 28.0% aggregate upside for SYK.
Article contains paid placements without independent editorial review.
Bullish Signals
Stryker (SYK) maintains a Strong Buy analyst consensus with a price target of $401.19, indicating significant upside potential.
Stifel Nicolaus analyst Rick Wise reiterated a Buy rating on Stryker with a $360.00 price target, while the current trading price is $294.73.
TipRanks – DeepSeek upgraded Stryker to a Buy rating and set a $326.00 price target.
Establishment Labs Holdings (ESTA) holds a Strong Buy analyst consensus with an average price target of $87.71, reflecting a 29.5% upside from current levels.
TD Cowen analyst Josh Jennings reiterated a Buy rating on Establishment Labs Holdings with a $90.00 price target.
Canaccord Genuity maintained a Buy rating on Establishment Labs Holdings with a $90.00 price target.
Risk Factors
Despite the bullish consensus, several major banks lowered their Stryker (SYK) price targets recently: Goldman Sachs cut it to $361 from $357 (though the text says raised, context implies mixed signals), Baird lowered to $385 from $437, Bernstein to $410 from $465, Evercore ISI to $355 from $365, and JPMorgan to $400 from $445.
Analyst Rick Wise of Stifel Nicolaus has a poor track record with an average return of -2.2% and a 43.8% success rate, suggesting limited reliability for his bullish $360 price target.
While the aggregate analyst consensus shows significant upside (28.0% for SYK), individual institutional investors are increasingly cautious, evidenced by multiple downgrades on price targets during the recent period.
The article is heavily promotional content that has not been reviewed or endorsed by Globe and Mail, containing paid placements which may introduce bias.
Medical technology company Stryker reported first-quarter 2026 results that missed Wall Street expectations on both revenue and earnings due to the disruptive timing of a cybersecurity incident. The company's revenue rose 2.6% year-over-year to $6.02 billion, but this was significantly below analyst estimates of $6.34 billion, marking a 5% miss. Similarly, non-GAAP adjusted earnings per share came in at $2.60 per share, which was 12.9% lower than the consensus estimate of $2.98, while non-GAAP adjusted EBITDA fell to $1.39 billion against an expected $1.57 billion. Management attributed these misses primarily to a late-quarter cyber incident that caused global system disruptions, resulting in production stoppages, delayed shipments, and varied impacts on revenue recognition across different business units, with capital equipment and made-to-order products suffering more than consumables.
Despite the quarter's underperformance, CEO Kevin Lobo stated that underlying demand remains healthy and the operational shutdowns constrained reported results rather than indicating a lack of customer interest or product viability. CFO Preston Wells noted that manufacturing operations were fully restored by early April thanks to swift action and effective backup systems that minimized permanent damage to customer relationships. Looking ahead for the remainder of 2026, Stryker has reiterated its full-year adjusted EPS guidance at $15 per share at the midpoint, unchanged from its previous outlook, expecting most lost sales from the cyber incident to be recovered over the rest of the year.
Management outlined a specific recovery cadence where catch-up revenue is anticipated to begin in the second quarter for some businesses while extending into the second half for others, with orthopaedics expected to recover earlier than capital-intensive med-surg products. The company highlighted continued momentum in its robotic systems, reporting record first-quarter installations for its Mako robotic system and preparing for the launch of Mako Shoulder on the latest platform. Additionally, Stryker has reorganized its Ortho Tech division by combining portfolios to streamline innovation and is pursuing the acquisition of Amplitude Vascular Systems to expand into peripheral vascular markets. The company plans to maintain its full-year operating margin improvement targets despite first-half headwinds from input cost inflation, tariffs, and rising raw material prices through operational discipline and procurement initiatives.
Investors will be watching the pace of revenue recovery from the cyber incident, specifically how quickly deferred sales are recognized across various product lines, as well as the execution on upcoming new product launches like Mako Shoulder and the Pangea trauma platform approvals in Europe and Japan. Stryker's stock traded at $293.91 following the earnings report, down from $315.28 prior to the announcement, reflecting immediate market reaction to the miss against expectations.
📉 Revenue missed estimates by 5% due to cyber-related production delays.
💸 EPS was $2.60, significantly trailing the analyst consensus of $2.98.
⚠️ Cyber incident caused shutdowns but margins expanded to a record 15.5%.
🔄 Company reorganized into Ortho Tech and reaffirmed full-year EPS guidance.
🚀 Mako robotic sales hit record highs while new product approvals await.
📉 Stryker reported Q1 revenue of $6.02 billion, missing Wall Street estimates of $6.34 billion due to a 5% shortfall.
💸 Non-GAAP earnings per share were $2.60, significantly below the analyst consensus of $2.98 by 12.9%.
⚠️ A late-quarter cyber incident caused operational shutdowns and production delays that disrupted revenue recognition across the company.
🤖 Management reaffirmed its full-year adjusted EPS guidance of $15 at the midpoint despite Q1 underperformance.
📈 Operating margins expanded to 15.5%, up from 14.3% in the previous year, offsetting some impact from the cyber event.
🔧 Manufacturing operations were fully restored by early April, with leadership crediting effective backup systems for rapid recovery.
🤖 Stryker achieved its best-ever first quarter for Mako robotic system installations, driven by high utilization and surgeon feedback.
🔄 The company reorganized into a new Ortho Tech division to streamline innovation and combine key product portfolios.
🤝 Stryker is nearing the acquisition of Amplitude Vascular Systems to expand its peripheral vascular market presence.
💰 Deferred revenue from Q1 delays is expected to be recognized throughout the remainder of the year in varying cadences.
🚀 New products like Mako Shoulder and Pangea trauma platform approvals are anticipated to drive continued growth.
🛡️ Management plans investments in cybersecurity and operational resilience following lessons learned from the recent incident.
💹 Input cost inflation from tariffs and raw materials will be managed through procurement initiatives and operational discipline.
📉 The stock price dropped from $315.28 to $293.91 following the earnings announcement and Q1 miss.
Bullish Signals
Stryker reaffirmed full-year Adjusted EPS guidance at $15 midpoint.
Operating margin expanded 150 bps to 15.5% versus prior year.
Mako robotic system recorded best-ever first quarter installations.
Mako Shoulder launch expected to boost joint replacement growth.
New Ortho Tech division improves speed to market and efficiency.
Award-pending Amplitude Vascular Systems acquisition expands vascular presence.
Mako Shoulder rollout and Pangea approvals drive above-market growth.
Cost initiatives offset inflation and tariffs for margin improvement.
Risk Factors
Missed revenue expectations by 2.6% and EPS by 12.9%.
Adjusted EBITDA missed estimates significantly with widening margins.
Cyber incident disrupted global systems causing production stoppages and delays.
Stock price dropped over $20 following poor execution results.
Tariffs and raw material costs threaten future margin improvements.
Bullish Signals
Management reiterated its full-year Adjusted EPS guidance of $15 at the midpoint, signaling confidence that Q1 impacts will be recovered over the rest of the year.
Operating margin expanded to 15.5% from 14.3% in the same quarter last year, demonstrating underlying operational strength.
Stryker reported its best-ever first quarter for Mako robotic system installations, driven by high utilization and positive feedback from surgeons.
The upcoming launch of the Mako Shoulder on the latest platform is expected to further boost growth in the joint replacement franchise.
A new Ortho Tech division was established to combine key portfolios, which aligns product lines for better speed to market and operational efficiency.
Management highlighted a pending acquisition of Amplitude Vascular Systems (AVS) to expand presence in the peripheral vascular market, alongside ongoing evaluation of additional M&A opportunities.
The company expects full rollout of the Mako Shoulder and approvals for the Pangea trauma platform in Europe and Japan to drive above-market growth.
Stryker plans to offset input cost inflation and tariffs through procurement initiatives and operational discipline to achieve targeted operating margin improvement for the full year.
Risk Factors
Stryker missed Wall Street revenue expectations by 2.6% year-on-year ($6.02B vs $6.34B estimates) and underperformed on non-GAAP profit with actual EPS of $2.60 versus the $2.98 analyst consensus (a 12.9% miss).
Adjusted EBITDA missed estimates by 11.5% at $1.39 billion compared to $1.57 billion, with margins falling short of projected performance.
A late-quarter cyber incident disrupted global systems, causing production stoppages, delayed shipments, and uneven revenue recognition impacts across capital equipment and made-to-order product lines.
The company faces operational shutdowns and variability in business units due to the cyberattack, requiring ongoing investments in cybersecurity and operational resilience despite having restored manufacturing by early April.
Stock price fell from $315.28 to $293.91 immediately following the earnings report, reflecting market concerns over the quarter's execution and future recovery trajectory.
Analysts are closely monitoring the pace and completeness of revenue recovery from the cyber incident, specifically watching for delays in capital-intensive MedSurg products scheduled for Q3 and Q4 catch-up.
The company plans to offset input cost inflation from tariffs and rising raw material prices through procurement initiatives, creating potential margin pressure despite targeted improvements.
BTIG analyst Ryan Zimmerman reaffirmed a Buy rating on Stryker (SYK), setting a price target of $379.00, while the stock closed at $315.13. TipRanks notes that Zimmerman covers the Healthcare sector with an average return of -0.6% and a 39.60% success rate. The broader analyst consensus for Stryker remains Strong Buy, with a price target consensus of $415.94, indicating potential upside of approximately 32%. Additionally, Canaccord Genuity also maintained its Buy rating on the stock with a $400.00 price target in their latest report.
Stryker reported strong financial results for the quarter ending December 31, delivering quarterly revenue of $7.17 billion and a net profit of $849 million, compared to $6.44 billion in revenue and $546 million in net profit from the prior year. The company also provided guidance for the current fiscal year, maintaining an adjusted EPS outlook between $14.90 and $15.10, which aligns closely with the consensus estimate of $14.96. Stryker reported a Q1 adjusted EPS of $2.60 against a consensus of $2.98.
Despite the bullish analyst sentiment and strong earnings growth, corporate insider activity currently shows negative sentiment on the stock due to recent selling by 53 insiders. Specifically, in February 2026, Director Ronda Stryker sold 500,000 shares for a total value of $181.7 million. This increase in insider selling contrasts with the positive external analyst ratings and recent financial performance.
📈 Analysts maintain strong Buy ratings with price targets ranging from $379 to $400.
📊 Stryker reported record Q4 revenue of $7.17B and profit growth of over 50%.
⚠️ Negative insider sentiment persists after Director Ronda Stryker sold $181M in shares.
📈 BTIG analyst Ryan Zimmerman reaffirmed a Buy rating on Stryker (SYK) with a price target of $379.00.
💰 Stryker shares closed at $315.13, presenting an opportunity for upside potential below the consensus price target of $415.94.
📊 The company reported Q4 revenue of $7.17 billion and net profit of $849 million, up from $6.44 billion and $546 million respectively in the prior year.
⚠️ Corporate insider sentiment is negative due to increased selling activity over the past quarter among 53 insiders.
👩💼 Director Ronda Stryker recently sold 500,000 shares for approximately $181.7 million in February 2026.
📉 Q1 adjusted earnings per share came in at $2.60, missing the analyst consensus estimate of $2.98.
🎯 Management maintained its full-year 2026 adjusted EPS outlook between $14.90 and $15.10, aligning closely with the consensus of $14.96.
⚖️ Despite the negative insider activity, the overall analyst consensus for Stryker remains Strong Buy.
🏥 Canaccord Genuity also maintained a Buy rating on the stock with a price target of $400.00.
🔍 Zimmerman covers the Healthcare sector including peers like GE Healthcare Technologies and Alcon.
📉 His historical performance shows an average return of -0.6% and a 39.60% success rate over his career.
J.P. Morgan analyst Robbie Marcus maintains a Buy rating on Stryker with a price target of $400, citing strong performance in the healthcare sector. While other analysts like Bernstein also issued a Buy rating recently, Deutsche Bank kept its Hold rating, and several other firms including BTIG, Needham, Canaccord, and Deutsche Bank lowered their price targets around that time.
Based on Stryker's Q4 earnings for the year ending December 31, the company reported quarterly revenue of $7.17 billion compared to $6.44 billion last year, with net profit rising from $546 million to $849 million.
However, insider sentiment is negative as corporate insiders have been selling shares; notably, Director Ronda Stryker sold 500,000 shares in February 2026 for over $181 million, contributing to a decline in insider confidence despite positive earnings.
📈 Analysts maintain Buy ratings with J.P. Morgan targeting $400.
💵 Q4 2025 revenue surged to $7.17B with net profit at $849M.
⚠️ Insider selling continues as Ronda Stryker offloaded $181M in shares.
📈 J.P. Morgan reaffirmed a Buy rating on Stryker (SYK) with a price target of $400.00 in a report released today.
💰 Robbie Marcus, the analyst covering the Healthcare sector at J.P. Morgan, maintains a 51% success rate on his recommended stocks.
✅ Bernstein's Lee Hambright also issued a Buy rating on Stryker in a separate report issued today.
⚠️ Deutsche Bank maintained a Hold rating on Stryker but lowered its price target from $397 to $379.
📉 Other analysts including BTIG, Needham, and Canaccord also lowered their price targets for SYK despite J.P. Morgan's Buy.
💵 Based on Q4 2025 earnings, Stryker reported quarterly revenue of $7.17 billion compared to $6.44 billion the prior year.
📊 Net profit reached $849 million in Q4 2025, up from $546 million during the same period last year.
⚠️ Corporate insider sentiment is negative due to increased selling activity over the past quarter by 53 insiders.
🤵 Ronda Stryker, a Director at SYK, sold 500,000 shares in February 2026 totaling over $181 million.
📰 This article contains third-party content and press releases which have not been reviewed by The Globe and Mail.
Bullish Signals
J.P. Morgan reiterated a Buy on Stryker (SYK) targeting $400.
Bernstein maintained a Buy rating following the latest earnings release.
Stryker Q4 revenue hit $7.17 billion, up from $6.44 billion last year.
Net profit surged to $849 million versus $546 million in the prior year.
Risk Factors
Mixed sentiment: J.P. Morgan Buy vs Deutsche Bank Hold.
Ronda Stryker sold 500k shares worth ~$181.7M in Feb 2026.
BTIG lowered price target from $397 to $379.
Deutsche Bank cut target from $402 to $315.
Needham and Canaccord reduced targets by $36 and $35.
Bullish Signals
J.P. Morgan reiterated a Buy rating on Stryker (SYK) with a price target of $400.00.
Bernstein also maintained a Buy rating on the stock following the latest earnings release.
For the quarter ending December 31, Stryker reported quarterly revenue of $7.17 billion, representing significant growth from last year's $6.44 billion.
Net profit surged to $849 million for the most recent quarter, compared to $546 million in the same period last year.
Robbie Marcus, the analyst covering Stryker, has an impressive track record with a 7.2% average return and a 51.00% success rate on recommended stocks.
Risk Factors
Despite a Buy rating from J.P. Morgan, Deutsche Bank maintained a Hold rating on Stryker (NYSE: SYK), indicating mixed analyst sentiment.
Corporate insider sentiment is negative with an increase in insider selling over the past quarter.
Ronda Stryker, a Director at SYK, sold 500,000 shares for approximately $181.7 million in February 2026, signaling significant insider exit.
BTIG lowered its price target to $379 from $397, suggesting a downgrade in valuation expectations.
Deutsche Bank reduced its price target to $315 from $402, reflecting a bearish outlook on the stock's upside potential.
Needham and Canaccord also cut their price targets by $36 and $35 respectively, indicating growing analyst concern.
Stryker Corporation (SYK) shares have fallen to $299.28, marking a drop of $15.85 or 5.03% in the current session. This decline puts the company on track for its lowest closing price since January 5, 2024, when it closed at $295.33. Additionally, the stock is poised for its largest percentage decrease since April 4, 2025, when it fell by 6.07%, while trading as low as $299.14 today, a level not seen since January 9, 2024. The decline has been consistent over the recent period, with the stock down three of the past four days and falling 8.62% this week, which is its worst weekly performance since the week ending June 17, 2022, when it dropped 10.31%.
Looking further at its performance metrics relative to historical data, Stryker's current price represents a decline of 25.83% from its all-time closing high of $403.53 achieved on July 25, 2025. The stock is also down 20.87% from its close one year ago on May 2, 2025, which was $378.22. In terms of intraday movements, the current fall of 5.07% at today's low marks the largest percentage decrease since March 12, 2026, when the stock fell as much as 5.08%. Furthermore, Stryker has emerged as the third worst performer in the S&P 500 for the day, signaling continued negative momentum across its price range and weekly trajectory.
📉 SYK dropped $15.85, its lowest close since January 2024.
📊 The stock is down 25.83% from its all-time high of $403.53.
⏳ Shares are currently 20.87% lower than their closing value 52 weeks ago.
📉 Stryker Corporation (SYK) is trading at $299.28, marking a 5.03% decline or a drop of $15.85 from its previous price.
📅 This stock price represents the lowest close since January 5, 2024, when it previously closed at $295.33.
⬇️ The company is on track for its largest percentage decrease since April 4, 2025, following an expected fall of 6.07%.
📉 SYK has decreased by three of the last four trading days and is down 8.62% this week.
📊 This weekly performance is the worst since the week ending June 17, 2022, when shares fell 10.31%.
💸 The current price reflects a drop of 25.83% from its all-time high of $403.53 reached on July 25, 2025.
⏳ Shares are currently down 20.87% compared to their closing value 52 weeks ago on May 2, 2025.
📉 The stock traded as low as $299.14 during the session, its lowest intraday level since January 9, 2024.
🔻 SYK's intraday drop of 5.07% represents the largest single-day percentage decrease since March 12, 2026.
🏆 In terms of today's performance, Stryker was the third worst-performing stock within the S&P 500 index.
⚠️ Investors should exercise independent judgment as this content is provided by a third party and not endorsed by Morningstar.
Risk Factors
Stryker Corporation (SYK) stock is trading at $299.28, which marks a significant decline of 5.03% from its previous close.
The stock is on track for its lowest closing price since January 2024, specifically targeting the low set on Jan. 5, 2024, of $295.33.
This represents the largest single-day percentage decrease since April 4, 2025, when it fell 6.07%.
The stock has underperformed for three out of the past four trading days, indicating sustained negative momentum.
SYK has declined 8.62% this week alone, marking its worst weekly performance since June 17, 2022, when it fell 10.31%.
The current price is down 25.83% from its all-time high of $403.53 reached on July 25, 2025.
Investors are facing substantial depreciation relative to the prior year, with the stock down 20.87% from its closing price a year ago (May 2, 2025).
The intraday trading low of $299.14 is the lowest level since January 9, 2024, suggesting continued pressure on the valuation.
MedSurg and Neurotechnology: $3.21 billion (ticker SYK)
CEO Kevin Lobo confirmed that a significant cyberattack in mid-March 'meaningfully' impacted Stryker's first-quarter 2023 financial results, though the company maintained its full-year guidance for organic sales growth between 8% and 9.5% and adjusted earnings per share of $14.90 to $15.10. The attack, initiated on March 11 by an Iran-linked threat actor known as Handala, disrupted Stryker's Microsoft environment, forcing a shutdown of ordering, shipping, and manufacturing operations for several weeks until the first week of April. Consequently, Q1 net sales reached $6 billion with only 2.6% year-over-year growth, a notable dip compared to the 10% to nearly 12% growth seen in every quarter of the previous year. RBC Capital Markets analyst Shagun Singh noted that the company missed consensus estimates for organic sales by approximately $317 million due to these disruptions.
Despite the operational setbacks, including the wiping of thousands of servers and mobile devices and the loss of 40,000 laptops, Stryker emphasized that it did not lose overall business, with CEO Kevin Lobo stating, "There isn't really any business I could think of that we've lost." The executive team expects a recovery trajectory in Q2 followed by continued growth in the remainder of the year to normalize the first-quarter results. Analysts from Stifel and J.P. Morgan remained confident in Stryker's long-term prospects, citing healthy end-market trends and consistent industry growth as reasons investors should gravitate toward the company now that the immediate cyber incident is behind them.
📉 Cyberattack distorted Q1 results, dropping organic sales growth to 2.6% from typical 10-12%.
🔒 Global Microsoft shutdown disrupted operations for weeks but core customer data remains safe.
CEO confident Q2 recovery meets targets despite cyberattack impact.
Analysts bullish on long-term prospects and end-market trends.
High-quality fastest-growing MedTech company poised for growth.
Stock favored as cyber incident impact passes.
Risk Factors
CEO admitted cyberattack meaningfully impacted Q1 results causing a significant miss.
Stryker Q1 sales growth of 2.6% is drastically lower than typical rates.
Cyberattack shut down operations for weeks and required wiping 40,000 laptops.
Iran-linked threat actor Handala claimed responsibility and stole sensitive data.
Current financial results are distorted by attack and face near-term volatility.
Bullish Signals
Despite a 'meaningful' impact from the cyberattack, Stryker maintained its full-year guidance for organic sales growth in the range of 8% to 9.5% and adjusted earnings per share between $14.90 and $15.10.
CEO Kevin Lobo expressed confidence that any business lost during the first quarter would be recovered, stating, 'We've come out of this very strong,' with executives anticipating recovery in Q2 and beyond to meet full-year targets.
Analysts remain bullish on Stryker's long-term prospects; Stifel analyst Rick Wise noted healthy end-market trends and expected rest-of-2026 business recovery suggest the company is poised for a strong growth year ahead.
J.P. Morgan analyst Robbie Marcus highlighted that Stryker remains one of the highest quality, consistently fastest growing companies in MedTech, with investors expected to gravitate towards the stock now that the cyber incident impact has passed.
Risk Factors
CEO Kevin Lobo admitted the cyberattack 'meaningfully' impacted first-quarter results, causing a significant miss against consensus estimates of approximately $317 million per RBC Capital Markets analyst Shagun Singh.
Stryker reported first-quarter sales growth of only 2.6%, which is drastically lower than the company's typical 10% to 12% annualized growth rate seen in every quarter of the prior year.
The cyberattack on March 11 shut down ordering, shipping, and manufacturing operations for weeks, forcing Stryker to wipe 40,000 laptops and disrupt its global Microsoft environment until the first week of April.
The Iran-linked threat actor Handala claimed responsibility for wiping thousands of servers and mobile devices and stealing data, introducing long-term security risks even after operations were restored.
While Stryker maintained full-year guidance, the company explicitly noted that current financial results are 'distorted' by the attack and will not normalize until the rest of the year, creating near-term earnings volatility.
The article announces that Stryker (NYSE: SYK), a global leader in medical technologies with products in MedSurg, Neurotechnology, and Orthopaedics, will participate in the Bank of America Securities 2026 Global Healthcare Conference. The event is scheduled for Wednesday, May 13, 2026, at the Encore at Wynn Hotel in Las Vegas, Nevada. A company presentation is set to occur at 1:40 p.m. Pacific Time, featuring Spencer Stiles, President and Chief Operating Officer; Jason Beach, Vice President and Group Chief Financial Officer for MedSurg and Neurotechnology; and Nick Mead, Vice President of Investor Relations. Viewers can access a live webcast and a subsequent replay through Stryker's investor relations website.
Stryker describes itself as being driven to make healthcare better alongside its customers, offering innovative products that improve patient and healthcare outcomes. The company states it impacts more than 150 million patients annually with its offerings worldwide. Contact information is provided for Nick Mead at 269-385-2600 or nick.mead@stryker.com, and for Kim Montagnino, Vice President of Chief Communications Officer, at the same number or kim.montagnino@stryker.com.
The news release is contextualized by a series of recent market updates regarding Stryker's stock price targets and analyst ratings found in the appended text from TipRanks and other sources. Over the past 24 hours, Goldman Sachs raised its price target to $361 from $357, while Baird lowered its target to $385 from $437. Similarly, Bernstein reduced its target to $410 from $465. Despite some conflicting analyst opinions highlighted in the source text regarding Moderna and Stryker, TD Cowen maintains a Hold rating on Stryker. The company also recently reported that its Q1 earnings and sales missed estimates due to cyber disruption, as noted in accompanying headlines.
📅 Stryker presents at BofA 2026 Healthcare Conference on May 13, 2026.
👥 Executives Spencer Stiles, Jason Beach, and Nick Mead will lead the session.
🏥 Global leader serves over 150 million patients annually across key medical segments.
📉 Recent sales miss linked to cyber disruption; analyst price targets remain mixed.
📅 Stryker (NYSE: SYK) will host a presentation at the Bank of America Securities 2026 Global Healthcare Conference on Wednesday, May 13, 2026.
📍 The event will take place at the Encore at Wynn Hotel in Las Vegas, Nevada, with Stryker's session scheduled for 1:40 p.m. Pacific Time.
👥 Spencer Stiles (President and COO), Jason Beach (VP and Group CFO), and Nick Mead (VP of Investor Relations) will represent Stryker at the conference.
🌐 The company's live webcast and a replay of the presentation will be available on its investor relations website after the event.
🏥 Stryker is a global leader in medical technologies with offerings in MedSurg, Neurotechnology, and Orthopaedics that serve over 150 million patients annually.
💰 Recent analyst actions show conflicting price targets, with Goldman Sachs raising their target to $361 while Baird and Bernstein have lowered theirs.
📉 Some analysts note recent quarterly challenges, including a sales miss in Q1 attributed to cyber disruption issues.
🏆 TD Cowen maintains a Hold rating on Stryker stock, indicating steady but cautious market sentiment among financial advisors.
🔗 Contact information for Nick Mead and Kim Montagnino is provided in the press release for investor inquiries regarding the conference.
⚠️ The company warns of potential future risks related to cybersecurity that impacted recent earnings performance.
Bullish Signals
Stryker is a global leader in medical technologies that impacts more than 150 million patients annually through its innovative products and services.
The company will present at the Bank of America Securities 2026 Global Healthcare Conference on Wednesday, May 13, 2026, providing an opportunity to discuss future growth with major stakeholders.
Key executives Spencer Stiles, Jason Beach, and Nick Mead will attend to highlight Stryker's strong leadership in MedSurg, Neurotechnology, and Orthopaedics.
Risk Factors
Stryker recently missed Q1 earnings and sales estimates due to cyber disruption, indicating operational vulnerabilities.
Multiple major investment banks have recently lowered their price targets for Stryker: Baird cut its target from $465 to $410, while Bernstein reduced theirs from $465 to $410.
Analyst sentiment is conflicted and negative, with a concurrent report noting analyst conflicts on Moderna and Stryker.
Despite one analyst (Goldman Sachs) raising their target to $361, two others (Baird and Bernstein) lowered targets from over $465 to the high $300s within just one day.
Stryker Corp reported disappointing first-quarter earnings driven by a significant cyberattack attributed to Iran-backed actors that disrupted operations from early March through April. The incident caused the company's growth to meaningfully miss Wall Street consensus estimates, with shares falling over 3% after the after-market close. Despite the operational setbacks, CEO Kevin Lobo stated that the company maintains its full-year guidance and remains well-positioned within its served markets, while also noting an expected acquisition of Amplitude Vascular Systems to close in the second quarter.
Financially, Stryker generated $745 million in adjusted earnings or $1.93 per share from $6.02 billion in sales for the quarter ending March 31, 2026. While the bottom line represented a 13.9% year-over-year increase and the top line grew 2.6%, the unadjusted EPS of $1.93 fell 38 cents short of the analysts' expected $2.98 per share on revenue that came in below the projected $6.33 billion. Stryker also announced organizational restructuring, combining its orthopedic instruments and Mako surgical robotics portfolios into a single Ortho Tech business to better serve orthopedic customers.
Analysts remain largely bullish on the stock despite the miss. BTIG analysts Ryan Zimmerman and Iseult McMahon maintained their Buy rating, arguing that market prices already reflect the risk of recouping lost sales and noting Stryker's strong track record and order book. Similarly, William Blair analysts led by Steven Lichtman kept a positive stance, citing confidence that most lost sales will be recovered through delayed revenue recognition or procedure pushouts, which is consistent with the company reiterating its guidance for 8.0% to 9.5% organic net sales growth and adjusted EPS between $14.90 and $15.10 for 2026.
📉 Q1 results missed consensus expectations due to March cyberattack disruptions.
🛡️ Company maintains full-year guidance despite significant Q1 operational impacts.
💼 Stryker acquires Amplitude Vascular Systems, expected to close in Q2.
🔄 New Ortho Tech business combines instruments and robotics portfolios.
⬇️ Stock fell over 3% as shares priced in recovery risks.
📉 Stryker (NYSE: SYK) reported first-quarter results that missed Wall Street analyst consensus primarily due to the operational disruption caused by an Iran-backed cyberattack in March.
📊 For Q1 ending March 31, 2026, Stryker earned $745 million or $1.93 per share from $6.02 billion in sales.
⚠️ The reported earnings were 38 cents below analyst expectations of $2.98 EPS and $6.33 billion in expected revenue.
🛡️ CEO Kevin Lobo stated that while growth was meaningfully impacted by the incident, the company is maintaining its full-year guidance.
💼 Stryker announced it is acquiring Amplitude Vascular Systems, with the deal expected to close in the second quarter.
🔄 The company made organizational changes by creating a new Ortho Tech business combining instruments and Mako surgical robotics portfolios.
🎯 Stryker maintains 2026 guidance for organic net sales growth of 8.0–9.5% and adjusted EPS of $14.90–$15.10.
⬇️ Shares fell over 3% to $302.59 following the earnings release, while the S&P 500 rose slightly by contrast.
📈 Adjusted Q1 EPS of $2.60 excluded one-time items related to the cyberattack remediation and lost sales.
💹 BTIG analysts maintained a Buy rating, suggesting the stock price already reflects the risk of recovering lost sales.
👍 William Blair analysts noted confidence that most lost sales will be recovered through delayed revenue or procedure pushouts this year.
🔍 The cyberattack disrupted Stryker's operations at its Michigan headquarters through early April.
📅 This article was originally published on April 30, 2026, and updated with next-day stock performance data.
Bullish Signals
Guidance: 8.0-9.5% organic net sales growth and $14.90-$15.10 EPS.
Profit up 13.9% to $745 million despite top-line pressure.
Acquiring Amplitude Vascular Systems, expected close in Q2.
Merging orthopedic instruments with surgical robotics portfolios.
BTIG maintains Buy rating on SYK recovery potential.
Experts confident lost sales will be recovered this year.
Risk Factors
Stryker missed Q1 EPS and sales targets.
Cyberattack disrupted operations and impacted growth.
Shares dropped 3% to $302.59 after market close.
Analysts warn prices already factor in recoupment risks.
Bullish Signals
Stryker maintained its full-year guidance for organic net sales growth of 8.0–9.5% and adjusted net earnings per diluted share of $14.90–$15.10, signaling strong management confidence despite the cyberattack.
The bottom line was up 13.9% year-over-year to $745 million, demonstrating underlying profitability even with top-line pressure.
Stryker recently announced an agreement to acquire Amplitude Vascular Systems, expected to close in the second quarter, providing a significant positive catalyst for growth.
The new Ortho Tech business combination aligns orthopedic instruments and surgical robotics portfolios, aiming to better serve customers and improve operational efficiency.
Analysts at BTIG maintain their Buy rating on SYK shares, noting that investors are pricing in the recovery potential given Stryker's strong track record and existing order book.
Industry experts from William Blair express confidence that most lost sales will be recovered through delayed revenue recognition and procedure pushouts within the current year.
Risk Factors
Stryker's Q1 earnings report missed Wall Street analyst consensus, recording $2.60 EPS versus the expected $2.98 and $6.020 billion in sales versus an anticipated $6.33 billion.
A major cyberattack by Iran-backed hackers disrupted Stryker's operations from early March through April, meaningfully impacting growth for the quarter that ended March 31, 2026.
Shares of SYK dropped more than 3% to $302.59 following the after-market-close earnings release, dragging down the stock despite the S&P 500 rising.
Despite maintaining full-year guidance, analysts note that share prices have already accounted for the risks associated with the need to recoup lost sales for the remainder of the year.
Sonablate, a medical technology company specializing in high-intensity focused ultrasound (HIFU) for non-invasive prostate cancer treatment, announced the appointment of Brad Saar to its Board of Directors on April 30, 2026. Saar, formerly the President of Stryker’s Medical Division, brings over 30 years of global medical technology leadership experience to the company. During his tenure at Stryker, he oversaw a multibillion-dollar business that achieved sustained double-digit growth and completed 15 acquisitions totaling $7.4 billion while driving global manufacturing expansion. His expertise is expected to aid Sonablate in expanding international adoption, increasing physician utilization, and advancing its "precision sound medicine" platform, which uses targeted ultrasound energy to treat disease with surgical-level precision while preserving patient function.
Sonablate's HIFU technology was FDA-cleared in the United States for prostate tissue ablation and is utilized as a non-invasive alternative to surgery and radiation by targeting specific prostate tissue without incisions. The company aims to increase adoption across the urology community through growing clinical engagement and physician education, particularly as interest shifts toward focal therapy and outpatient care models. Saar noted that prostate cancer treatment is reaching an inflection point where non-invasive approaches are moving beyond early adoption into broader clinical consideration, driven by a priority to preserve quality of life.
As part of its ongoing growth strategy, Sonablate will participate in upcoming industry meetings this May, including the ASCA + SAMBA 2026 Conference & Expo and the American Urological Association Annual Meeting (AUA2026). At AUA2026, the company plans to host educational sessions on real-world HIFU use, patient selection, and the role of focal therapy in treating both prostate cancer and benign prostatic hyperplasia (BPH). These efforts are supported by initiatives such as the FUSION Global Registry, which aims to generate real-world evidence for validation and adoption. Sonablate CEO Richard Yang stated that with experienced leadership like Saar's and growing clinical interest, the company is well-positioned to scale globally and advance precision sound medicine as a foundational approach to treating prostate disease.
Sonablate positions itself as a global leader in non-invasive, focused ultrasound technologies, with its Sonablate® HIFU system having received regulatory approvals in more than 50 countries worldwide. The addition of Saar to the board reflects the company's continued focus on supporting the evolution of prostate cancer treatment toward precise, non-invasive, and function-preserving approaches. This strategic move underscores Sonablate's commitment to positioning precision sound medicine at the forefront of the next generation of urologic care while continuing to build clinical engagement within the medical community.
👤 Sonablate appointed Brad Saar, former Stryker Medical President, to its Board.
💰 Saar oversaw 15 acquisitions totaling $7.4B during his Stryker tenure.
🌍 HIFU technology holds FDA clearance and approvals in over 50 countries globally.
🗓 Company will present at ASCA + SAMBA 2026 and AUA Annual Meeting.
👤 Sonablate appointed Brad Saar, former Stryker Medical Division President, to its Board of Directors.
🏥 Saar brings over 30 years of global medical technology leadership experience from Stryker.
💰 During his tenure at Stryker, he oversaw a multibillion-dollar business with 15 acquisitions totaling $7.4 billion.
🚗 Sonablate's HIFU technology is FDA-cleared in the U.S. for non-invasive prostate tissue ablation without incisions.
🎯 The company's "precision sound medicine" platform aims to preserve patient function while treating disease with surgical-level precision.
📈 Saar expressed that prostate cancer treatment is reaching an inflection point where non-invasive approaches are gaining broader clinical consideration.
🗓️ Sonablate will participate in the ASCA + SAMBA 2026 Conference & Expo and AUA Annual Meeting both in May 2026.
🎤 At AUA2026, Sonablate will host educational sessions on real-world use of HIFU for prostate cancer and benign prostatic hyperplasia (BPH).
🌍 The company's FUSION Global Registry is ongoing to generate real-world evidence supporting the platform's validation and adoption.
🎉 A Women in Focal Therapy Leadership forum will convene during the AUA2026 meeting to advance education and collaboration.
🤝 CEO Richard Yang noted that Sonablate is well-positioned to scale globally with experienced leadership and growing clinical interest.
🌐 Sonablate's HIFU system has received regulatory approvals in more than 50 countries worldwide beyond the United States.
💡 The company focuses on expanding international adoption and increasing physician utilization of the focused ultrasound platform.
🧠 Saar's experience scaling global medtech platforms is expected to support advancing Sonablate’s platform to the next growth phase.
🔒 Both Stryker Medical Division and Sonablate prioritize treatments that aim to preserve quality of life for patients.
Bullish Signals
Sonablate appointed Brad Saar to its Board of Directors.
Saar brings 30+ years experience leading $7.4B at Stryker.
Sonablate's HIFU technology is FDA-cleared and approved in 50+ countries.
Sonablate plans to attend key industry meetings in May 2026.
The company will host educational sessions on HIFU applications.
CEO Yang says Sonablate is well positioned for global growth.
AUA2026 will include a Women in Focal Therapy Leadership forum.
Risk Factors
Saar led $7.4B acquisitions at Stryker.
May pursue aggressive dilutive acquisition strategy.
FDA clearance limited to US market only.
Over 50 countries approval implies complex regulatory.
No financial results, revenue or profit disclosed.
Bullish Signals
Sonablate announced the appointment of Brad Saar, former President of Stryker's Medical Division, to its Board of Directors to support growth.
Brad Saar brings more than 30 years of experience in global medical technology leadership and previously delivered sustained double-digit growth while leading 15 acquisitions totaling $7.4 billion at Stryker.
Sonablate's HIFU technology is FDA-cleared in the United States and has received regulatory approvals in more than 50 countries worldwide.
The company plans to participate in high-profile industry meetings including the ASCA + SAMBA 2026 Conference & Expo and the American Urological Association Annual Meeting (AUA2026) in May to increase physician adoption and awareness.
Sonablate will host educational sessions and discussions focused on real-world use of HIFU, patient selection, and its application in both prostate cancer and benign prostatic hyperplasia (BPH).
CEO Richard Yang stated that with experienced leadership and growing clinical interest, Sonablate is well positioned to scale globally and advance precision sound medicine as a foundational approach to treating prostate disease.
The company is convening clinical and industry stakeholders during AUA2026, including a Women in Focal Therapy Leadership forum focused on advancing education, collaboration, and leadership.
Risk Factors
The article highlights Brad Saar's previous experience with acquisitions at Stryker, totaling $7.4 billion across 15 deals, which may suggest Sonablate is likely to pursue a similar aggressive acquisition strategy that could dilute existing shareholders.
Sonablate relies on FDA clearance for only the United States market and has regulatory approvals in more than 50 countries worldwide, indicating potential dependency on international regulatory pathways that are often slower or more costly to navigate.
The announcement focuses entirely on Brad Saar joining the board, with no mention of Sonablate's current financial results, revenue growth, or profitability metrics, raising questions about the company's standalone performance without this high-profile appointment.
Stryker Inc. (SYK) is preparing to report its first-quarter 2026 earnings amid a recent cybersecurity disruption that has raised concerns regarding operational risks, costs, and margin execution. Analysts are closely monitoring the company's MedSurg and Neurotechnology segments, expecting approximately 8% year-on-year revenue growth despite the security incident. The market view relies on resilient global procedure volumes and Stryker's innovation pipeline in robotics and MedSurg to drive value, but the cyber event highlights potential challenges related to incremental cost pressures from tariffs and higher interest expenses that could impact reported margins near the end of this fiscal quarter.
Investment analysts at Simply Wall St project long-term targets for Stryker of $32.0 billion in revenue and $6.1 billion in earnings by 2029, which implies an 8.4% yearly revenue growth rate and an increase of about $2.9 billion from the current $3.2 billion earnings base. Based on these projections, the platform calculates a fair value estimate of US$419.11, representing a 33% upside to the current stock price. However, there is a divergence in community sentiment regarding this valuation, with six members of the Simply Wall St Community placing their own fair value estimates between US$340.49 and US$419.11, reflecting varying assumptions about growth versus execution risk.
The article concludes by emphasizing that investors must weigh both the strong growth expectations tied to robotics and procedural demand against operational disruptions like the cybersecurity incident and ongoing tariff costs. Simply Wall St provides a "Snowflake" visual analysis tool for evaluating Stryker's overall financial health, summarizing key rewards and warning signs without issuing a direct recommendation to buy or sell. The content is presented as general information based on historical data and unbiased methodology, noting that the analysis may not factor in the latest price-sensitive announcements and does not account for individual investor objectives.
📈 Analysts forecast 8% revenue growth driven by MedSurg and Neurotech demand.
💼 Fair value estimates range from $340 to $419, suggesting upside potential.
⚠ Execution risks include tariffs, interest costs, and operational disruption impacts.
🧭 Long-term targets aim for $32B revenue and $6.1B earnings by 2029.
🦠 Stryker (SYK) recently experienced a cybersecurity disruption that investors are monitoring closely ahead of its Q1 2026 earnings report.
📈 Analysts anticipate approximately 8% year-over-year revenue growth for the upcoming quarter, driven by demand in MedSurg and Neurotechnology segments.
💻 Investors are reassessing how near-term operational challenges from the cyber disruption could impact costs and margins despite strong procedural demand.
🔮 Long-term projections estimate Stryker will reach $32.0 billion in revenue and $6.1 billion in earnings by 2029, requiring consistent growth execution.
🧭 Simply Wall St analysis projects a fair value of $419.11 for SYK, suggesting a potential 33% upside to its current share price.
⚖️ Community estimates on the stock's fair value vary widely between $340.49 and $419.11, highlighting diverse assumptions regarding risk and growth.
⚠️ Rising cost pressures from tariffs and higher interest expenses alongside the cyber disruption present execution risks to current earnings guidance.
🛡️ To own Stryker successfully, investors must believe in resilient global procedure volumes and a deep innovation pipeline in robotics and MedSurg.
📉 The Q1 2026 earnings release serves as the key reference point for how operational issues reflect in margins and validate demand trends.
🧬 Stryker's broader investment narrative is being re-evaluated based on how reported growth matches analyst expectations for robotics and innovation.
🏢 The company aims to demonstrate disciplined execution across complex hospital systems despite recent cybersecurity events.
⚡ This article serves as a fundamental analysis summary intended for research rather than specific financial advice or buy/sell recommendations.
Bullish Signals
Stryker ($SYK) projects $32B revenue and $6.1B earnings by 2029.
Analysts expect 8% YoY revenue growth in Q1 2026.
Simply Wall St fair value of $419.11 shows 33% upside.
Fair value estimates range $340.49 to $419.11, offering safety.
Tariffs and interest expense could hurt earnings trajectory.
Disruption raises concerns about Q1 2026 MedSurg/Neurotech demand.
Fair value estimates range US$340.49 to US$419.11.
Bullish Signals
The article projects Stryker ($SYK) revenue of $32.0 billion and earnings of $6.1 billion by 2029, representing significant long-term growth potential.
Analysts expect around 8% year-on-year revenue growth in Q1 2026, reflecting sustained demand for procedures, robotics, and product innovation.
Simply Wall St analysis indicates a fair value of $419.11, which represents a 33% upside to the current price.
The community's fair value estimates range between US$340.49 and US$419.11, suggesting a wide margin of safety for investors.
Risk Factors
Recent cybersecurity disruption highlights significant operational risk around costs, margins, and execution on existing guidance.
Incremental cost pressures from tariffs and higher interest expense could challenge the current earnings trajectory investors have built into their expectations.
The recent cybersecurity disruption appears unlikely to change the key near term catalyst but raises concerns about how first quarter 2026 results will reflect demand in MedSurg and Neurotechnology.
Despite projected growth, investors must weigh both growth expectations and execution risk when comparing fair value estimates that range widely from US$340.49 to US$419.11.
Stryker Corporation (NYSE: SYK) announced that its 2026 Annual Meeting of Shareholders will be held virtually on Wednesday, May 6, 2026, at 12:00 p.m. Eastern Time. The live webcast will feature audio and slide presentations accessible via the company's investor relations website. A recording of the meeting will be available starting Thursday, May 7, 2026, at 10:30 a.m. ET until the definitive proxy statement for the subsequent 2027 annual meeting is filed.
The announcement coincides with routine governance disclosures and follows recent cybersecurity updates. On the day of publication, SYK shares declined 0.92% to $335.67, trading below its 200-day moving average. The stock fell alongside key medical device peers such as Boston Scientific (BSX), Medtronic (MDT), and Zimmer Biomet (ZBH), suggesting a broader sector weakness rather than company-specific distress.
Recent product launches, including the SmartHospital digital platform and new orthopaedic systems like Synchfix EVT and T2 Alpha, have shown mixed market reactions ranging from slight gains to small pullbacks. This annual meeting announcement is viewed as standard governance activity, with investors likely to focus on strategic commentary and risk disclosures delivered during the virtual gathering.
📅 Annual Meeting set for May 6, 2026 at 12:00 p.m. ET.
🌐 Event held virtually with live audio and slide presentations online.
📼 Recording available starting May 7, 2026 at 10:30 a.m. ET.
📉 SYK shares dropped 0.92% to $335.67 on announcement day.
🤝 Stock fell alongside peers BSX, MDT, ZBH, and ABT.
📅 Stryker's 2026 Annual Meeting of Shareholders is scheduled for Wednesday, May 6, 2026, at 12:00 p.m. ET.
🌐 The event will be conducted virtually via the internet with live audio and slide presentations available online.
📼 A recording of the meeting will be accessible starting Thursday, May 7, 2026, at 10:30 a.m. ET.
📉 SYK shares declined 0.92% on the day of the announcement, trading at $335.67.
🤝 The stock fell in tandem with peers BSX, MDT, ZBH, and ABT, indicating a broadly negative medical devices tape.
🚀 Recent product launches like SmartHospital and Synchfix EVT have elicited mixed price reactions ranging from -0.88% to +0.73%.
📜 The meeting follows the filing of a definitive proxy statement outlining governance practices and executive compensation.
🔒 Stryker recently issued cybersecurity 8-K updates prior to this annual meeting announcement.
Bullish Signals
SmartHospital platform connects devices and teams.
New Synchfix EVT and T2 Alpha systems launched.
Impacts 150 million patients annually globally.
Risk Factors
Trading below 200-day moving average at $372.67.
Down 17.09% from 52-week high.
Inconsistent market reactions to product headlines.
Bullish Signals
Stryker continues to drive innovation with recent launches including the SmartHospital digital platform connecting devices and teams.
The company has introduced new orthopaedic products such as Synchfix EVT for flexible syndesmotic ankle fixation and the T2 Alpha Humerus Nailing System.
Stryker impacts more than 150 million patients annually through its global portfolio in MedSurg, Neurotechnology, and Orthopaedics.
The annual meeting provides a structured opportunity for shareholders to vote on key items like board elections and executive pay.
Risk Factors
SYK shares are currently trading below the 200-day moving average at $372.67, indicating some downward price pressure.
The stock is down 17.09% from its 52-week high, reflecting recent market weakness in the sector.
Recent product and innovation headlines have generated inconsistent market reactions, with no consistent directional pattern observed.
Stryker Corp.'s operational capabilities remain significantly impaired following a sustained cyberattack that has forced its ordering and shipping systems to stay offline. The medical technology company is actively working to restore these critical functions but continues to face substantial challenges in addressing the severity of the breach, which was claimed by a group linked to Iran. This disruption has left Stryker unable to fulfill standard operational needs for its business, indicating an ongoing vulnerability that affects its supply chain and customer service capabilities.
The incident highlights the increasing threat landscape facing critical infrastructure providers, particularly within the healthcare sector. While specific financial impacts or detailed technical data regarding the extent of the data compromised have not been disclosed in this brief report, the persistence of the outage suggests a sophisticated and persistent intrusion. The involvement of a cyber group with geopolitical affiliations points to the potential for such attacks to have broader implications beyond mere operational disruption, raising concerns about security protocols at major medical technology firms.
🚑 Stryker Corp.'s ordering and shipping systems remain offline after a cyberattack.
🔐 An Iran-linked hacking group claimed responsibility for the incident.
📉 Operational disruptions continue to impair the medical technology company's functions.
🚑 Stryker Corp.'s ordering and shipping systems remain offline following a cyberattack.
🔐 The incident was claimed by a hacking group linked to Iran.
📉 Ongoing operational disruptions are affecting the medical technology company's ability to function normally.
Bullish Signals
The article does not contain positive aspects about Stryker, as it only reports on a cyberattack disrupting operations without mentioning any mitigating factors, successful recovery steps, or future upside.
Risk Factors
Stryker Corp.'s ordering and shipping systems remain offline due to an ongoing cyberattack, disrupting normal operations.
The cyberattack is attributed to a pro-Iran group that labeled it 'crippling', indicating severe impact on the company's capabilities.
Firm continues to struggle to address the hack, suggesting prolonged downtime and potential recovery challenges.
Stryker, a major medical supply company based in Portage, Michigan, announced that its systems were disrupted by a cyberattack believed to have originated from Iran. The company stated that the incident is contained and does not believe ransomware or malware has entered their systems. Stryker confirmed that the disruption is limited to their internal Microsoft environment.
In a statement released early Friday morning, Stryker emphasized that their core products, including Mako, Vocera, and LIFEPAK35, remain fully safe for use. The company maintains visibility into orders entered before the event, which will be shipped once system communications are restored. Orders received after the incident are currently being examined to ensure integrity.
Cybersecurity expert Leon DuPree from Eastern Michigan University noted that such attacks often occur during geopolitical tensions and serve as a message to disrupt normal organizational functions. He urged organizations to assume they are under cyberattack and take necessary defensive steps, highlighting that traditional warfare has evolved into digital threats affecting critical infrastructure.
🇮🇷 Iran-linked cyberattack disrupted Stryker's internal Microsoft systems this week.
✅ Incident contained with no malware detected on core medical products.
📦 Pre-event orders ship after system restoration; post-event orders under review.
💬 Employee email and phone communications remain safe within facilities.
⚠️ Experts warn of active threats due to geopolitical tensions.
🇮🇷 A cyberattack believed to originate from Iran disrupted Stryker's systems this week.
✅ Stryker confirmed the incident is contained within their internal Microsoft environment with no malware detected.
🛡️ Core medical products like Mako, Vocera, and LIFEPAK35 are fully safe for use by customers and patients.
📦 Pre-event orders will be shipped once system communications are restored following the disruption.
🔍 Post-event orders are currently being examined to ensure data integrity before processing.
💬 Stryker maintains that communication with employees via email and phone remains safe within facilities.
🎓 Cybersecurity expert Leon DuPree linked the attack to ongoing geopolitical tensions and state-sponsored disruption tactics.
⚠️ Experts warn that organizations must assume active cyber threats in current global security environments.
Bullish Signals
No malware or ransomware detected in Stryker systems.
Stryker, a major U.S. medical equipment company headquartered in Portage, Michigan, reported on Wednesday that a cyberattack disrupted its global networks. In a statement released on the company's website, Stryker CEO Kevin Lobo confirmed the incident was contained and noted there was no indication of ransomware or malware involvement. The attack targeted Microsoft programs within the organization, but specific details regarding data breaches or system damages remain under investigation by internal teams who are working to understand the full scope of the impact on their operations.
The cyberattack has drawn attention for its potential geopolitical implications. According to a report from The Wall Street Journal, the logo of Handala, a hacking group linked to Iran, has appeared on Stryker login pages, pointing toward a state-sponsored origin for the intrusion. Alexander Leslie, a senior adviser at threat intelligence company Recorded Future, described the incident as significant due to the escalation in target choice and effect, noting that attacking a high-profile U.S. healthcare manufacturer creates outsized strategic and political ripple effects. Stryker indicated in a filing with the Securities and Exchange Commission that they were still determining the full extent of the timeline for restoration and the impact on business.
Stryker, which employs approximately 56,000 people worldwide, produces a variety of medical products including artificial joints and hospital beds. While the company had reported revenue figures exceeding $25 billion in 2025, they have not yet provided a precise date for when systems will be fully restored to normal function. As of now, emails sent to Stryker requesting additional information regarding the cyberattack were not immediately answered, leaving stakeholders waiting for further updates on the security incident's resolution and potential data exposure.
🏥 Stryker, a major US manufacturer, reported a cyberattack disrupting global networks.
🛡️ No ransomware detected; the incident is contained while impact is investigated.
💻 Attack specifically targeted Microsoft programs within Stryker's infrastructure.
⚠️ Full restoration timeline and business impact remain undetermined per SEC filing.
🎯 Hacking group Handala, linked to Iran, displayed its logo on login pages.
🏥 Stryker, a major U.S. medical equipment manufacturer based in Portage, Michigan, reported a cyberattack that disrupted its global networks.
🛡️ The company stated it has no indication of ransomware or malware and believes the incident is contained while teams investigate system impact.
💻 The attack specifically affected Microsoft programs within Stryker's infrastructure according to the company's official statement.
⚠️ A filing with the Securities and Exchange Commission indicates the full timeline for restoration and business impact remain undetermined.
🎯 Security logs show the logo of Handala, a hacking group linked to Iran, appeared on company login pages as per The Wall Street Journal.
💰 Stryker reported revenue exceeding $25 billion in 2025 and employs approximately 56,000 people globally across various medical products.
📉 Experts note the strategic significance of targeting high-profile U.S. healthcare manufacturers for potential political ripple effects.
🕵️ Recorded Future senior adviser Alexander Leslie highlighted the escalation in target choice and effect for this type of cyber incident.
Bullish Signals
Stryker confirmed the cyberattack incident is contained, with no indication of ransomware or malware as of the report.
The company has experienced significant financial success, generating revenue of more than $25 billion by 2025.
With a large global workforce of 56,000 employees, Stryker maintains a robust operational footprint in the medical equipment sector.
Risk Factors
Stryker's global networks were disrupted by a cyberattack, with the full scope of impact on business still unknown.
The timeline for full restoration remains uncertain as teams work to understand the attack's consequences.
A hacking group linked to Iran (Handala) has appeared on company login pages, raising geopolitical security concerns.
Stryker's Microsoft programs were specifically targeted, indicating vulnerabilities in enterprise software infrastructure.
There is no immediate information available regarding emails seeking additional impact details from the company.
Stryker CEO Kevin Lobo faces operational scrutiny as cybersecurity incidents could affect patient care delivery systems.
With $25 billion in revenue at stake, any prolonged disruption poses significant financial and reputational risks.
Your Privacy
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Measure audience engagement and site statistics to understand how our services are used (Google Analytics)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
You can accept all cookies or configure your preferences. You can change them at any time via the "Manage Cookies" link in the footer.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Analytics cookies
Help us understand how visitors interact with our website using Google Analytics. These cookies collect information anonymously.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
